GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,733.50p
   
  • Change Today:
      5.00p
  • 52 Week High: 1,743.00p
  • 52 Week Low: 1,316.00p
  • Currency: UK Pounds
  • Shares Issued: 4,144.92m
  • Volume: 4,237,111
  • Market Cap: £71,852m
  • RiskGrade: 129

FDA extends review period of GSK blood cancer drug momelotinib

By Michele Maatouk

Date: Friday 16 Jun 2023

LONDON (ShareCast) - (Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.
The review period has been extended by three months to provide time to review recently submitted data.

"GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review," it said.

Momelotinib is not currently approved in any market.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,733.50p
Change Today 5.00p
% Change 0.29 %
52 Week High 1,743.00p
52 Week Low 1,316.00p
Volume 4,237,111
Shares Issued 4,144.92m
Market Cap £71,852m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
25.74% above the market average25.74% above the market average25.74% above the market average25.74% above the market average25.74% above the market average
68.63% above the sector average68.63% above the sector average68.63% above the sector average68.63% above the sector average68.63% above the sector average
Price Trend
49.19% above the market average49.19% above the market average49.19% above the market average49.19% above the market average49.19% above the market average
70.91% above the sector average70.91% above the sector average70.91% above the sector average70.91% above the sector average70.91% above the sector average
Income
8.79% above the market average8.79% above the market average8.79% above the market average8.79% above the market average8.79% above the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
22.96% below the market average22.96% below the market average22.96% below the market average22.96% below the market average22.96% below the market average
37.14% above the sector average37.14% above the sector average37.14% above the sector average37.14% above the sector average37.14% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 16-May-24 22-Feb-24
Paid 11-Jul-24 11-Apr-24
Amount 15.00p 16.00p

Trades for 03-May-2024

Time Volume / Share Price
15:21 6 @ 1,731.50p
15:01 0 @ 1,733.50p
16:49 185 @ 1,733.50p
16:35 1,624,313 @ 1,733.50p
16:35 2,000 @ 1,733.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page